Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Payables (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Payables for 16 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Payables fell 23.71% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, down 23.71% year-over-year, with the annual reading at $3.7 million for FY2025, 23.71% down from the prior year.
  • Payables for Q4 2025 was $3.7 million at Harvard Bioscience, down from $5.2 million in the prior quarter.
  • The five-year high for Payables was $7.5 million in Q2 2021, with the low at $3.7 million in Q4 2025.
  • Average Payables over 5 years is $5.6 million, with a median of $5.7 million recorded in 2021.
  • The sharpest move saw Payables surged 31.28% in 2022, then crashed 30.75% in 2023.
  • Over 5 years, Payables stood at $4.9 million in 2021, then soared by 31.28% to $6.4 million in 2022, then dropped by 13.85% to $5.6 million in 2023, then fell by 13.81% to $4.8 million in 2024, then fell by 23.71% to $3.7 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $3.7 million, $5.2 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.